Who is sponsoring NCT00329693?

NCT00329693 is sponsored by Ferring Pharmaceuticals.

What drugs are being tested in NCT00329693?

Interventions in NCT00329693: Norprolac, Norprolac, Norprolac, Norprolac.

What condition does NCT00329693 study?

NCT00329693 studies Ovarian Hyperstimulation Syndrome.

Is NCT00329693 still recruiting?

NCT00329693 is currently completed. Last updated 18 May 2011.

Last reviewed 2011-05-18 · How we verify

NCT00329693

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.

Completed Phase 2 Last updated 18 May 2011

What this trial tests

Phase 2 trial testing Norprolac in Ovarian Hyperstimulation Syndrome in 182 participants. Completed in 1 May 2008.

Timeline

1 June 2006

Primary endpoint
1 August 2007

1 May 2008

Quick facts

Lead sponsor	Ferring Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	182
Start date	1 June 2006
Primary completion	1 August 2007
Estimated completion	1 May 2008
Sites	7 locations across Spain

Drugs / interventions tested

Norprolac — full drug profile →
Norprolac — full drug profile →
Norprolac — full drug profile →
Norprolac — full drug profile →

Conditions studied

Ovarian Hyperstimulation Syndrome — all drugs for Ovarian Hyperstimulation Syndrome →

Sponsor

Ferring Pharmaceuticals — full company profile →

Who can join

Adults 21 to 37, female only, with Ovarian Hyperstimulation Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

OHSS
Time frame: 41 days after hCG injection

Sponsor's own description

Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.
Busso C, Fernández-Sánchez M, García-Velasco JA, Landeras J, et al · · 2010 · cited 36× · PMID 20139430 · DOI 10.1093/humrep/deq005

Verify or expand the search:

Other Ferring Pharmaceuticals trials

Trials by the same sponsor.

NCT07152730 — A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump · Phase 1 · withdrawn
NCT07029451 — To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patt · recruiting
NCT06668493 — Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis · Phase 1, PHASE2 · recruiting
NCT06545955 — A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in · Phase 3 · recruiting
NCT06510374 — Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Can · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00329693 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ferring Pharmaceuticals
Last refreshed: 18 May 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00329693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing